FIG 2.

Disease stabilization with lorlatinib and bevacizumab. In patient B, axial contrast T1 weighted images of (left) baseline and (right) follow-up after 17 weeks of combination treatment are shown. The combination of lorlatinib and bevacizumab resulted in stabilization of anterior parafalcine dural metastasis with only a slight increase in a right temporal occipital dural metastasis, recognizing that the patient’s intracranial disease had substantially progressed while receiving prior treatment with single-agent lorlatinib.